WellSpring Pharma Services on Thursday announced millions in new equipment purchases and a strategic partnership to produce drugs for the U.S. market.
The Canadian pharmaceutical contract manufacturer said that its $3 million capital investment would provide new expertise in production for early clinical trials and, in the future, enable expansion of its large-scale manufacturing.
In particular, it will provide scalable development capabilities, expanded production of specialized dosage forms — such as bilayer tablets — and support for high-potency compound manufacturing.
“We’re now better equipped to offer our clients services from small-scale development and scale-up to large-scale manufacturing, packaging and distribution,” company president David Mayers said in a statement.
The new equipment includes an Alexanderwerk Roller Compactor, an IMA Precisa capsule weight checker, an O’Hara Tray Drying oven and Aqueous Film Coater, a Korsch XL 400 Tablet Press, a Glatt GPCG 2/5 Fluid Bed Processor and a 5L Becomix Counter sweep vessel.
WellSpring will detail the capital expansion and new branding at the annual INTERPHEX trade show later this month.
In addition, the company announced a partnership with IDT Australia to produce several products at WellSpring’s facility near Toronto. The agreement includes the cardiac drug Pindolol, which Wellspring valued at $10 million on the U.S. market.
IDT is aiming to establish itself as a specialty generics business and is commercializing 24 drugs for sale via U.S. distributors.